{"id":2722,"date":"2026-08-27T10:00:00","date_gmt":"2026-08-27T14:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2722"},"modified":"2026-08-27T19:24:18","modified_gmt":"2026-08-27T23:24:18","slug":"tezspire-meets-both-phase-iii-endpoints-in-eosinophilic-esophagitis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2722","title":{"rendered":"Tezspire Meets Both Phase III Endpoints in Eosinophilic Esophagitis"},"content":{"rendered":"

Companies:<\/strong> AstraZeneca \/ Amgen · Drug:<\/strong> Tezspire (Tezepelumab) · Trial:<\/strong> CROSSING (Phase III) · Indication:<\/strong> Eosinophilic Esophagitis · Date:<\/strong> August 27, 2026<\/p>\n

\"20260827_AstraZeneca_Amgen_Tezspire_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

AstraZeneca and Amgen reported that the 368-patient Phase III CROSSING trial of tezepelumab in eosinophilic esophagitis met both co-primary endpoints at Week 24: histologic remission and improvement in dysphagia. Both tested doses also met all key secondary endpoints, with effects described as sustained through Week 52. The result expands clinical validation of upstream thymic stromal lymphopoietin blockade into a third epithelial-driven inflammatory disease, but response rates, effect sizes, subgroup results and detailed safety data remain undisclosed.<\/p>\n

What Happened<\/h4>\n

CROSSING randomized adults and adolescents aged 12 to 80 with symptomatic, histologically active disease in a 1:1:1 ratio to low-dose tezepelumab, high-dose tezepelumab or placebo, administered subcutaneously every four weeks, with stable background proton-pump inhibitors and swallowed topical corticosteroids permitted. At Week 24, both tezepelumab doses reportedly improved the proportion of patients achieving six or fewer peak esophageal eosinophils per high-power field and reduced Dysphagia Symptom Questionnaire scores versus placebo. Key Week 52 endpoints included histologic and symptom responses, endoscopic disease features, histologic severity and extent, inflammatory remission and total endoscopic remission. The companies stated that safety was generally consistent with approved Tezspire indications but did not provide adverse-event frequencies, discontinuations, serious infections, hypersensitivity, dose-response separation or placebo-adjusted efficacy estimates; full data are planned for a future medical meeting and regulatory submission.<\/p>\n

Deep Analysis<\/h4>\n

Eosinophilic esophagitis requires improvement in both tissue inflammation and patient-experienced swallowing difficulty; biologic programs can produce strong histologic change without proportional symptom benefit. Meeting both co-primary endpoints therefore clears an important clinical-design hurdle, although clinical magnitude cannot be judged until numerical data and missing-data handling are available. Tezepelumab blocks TSLP, an epithelial alarmin positioned upstream of multiple inflammatory cascades; efficacy in asthma, chronic rhinosinusitis with nasal polyps and now EoE supports a cross-organ epithelial-inflammation thesis, but does not establish uniform benefit across EoE endotypes, durability beyond one year or superiority to approved downstream biologics. Commercial and regulatory differentiation will depend on absolute remission rates, symptom effect size, onset, dose selection, background-therapy interaction, adolescent consistency, administration burden and safety, with competition including dietary and topical therapy, proton-pump inhibitors, dilation and biologics such as dupilumab.<\/p>\n

Company and Product Background<\/h4>\n

Eosinophilic esophagitis is a chronic immune-mediated disorder in which epithelial dysfunction and type 2 inflammation drive eosinophil infiltration, remodeling, dysphagia, food impaction and strictures; diagnosis generally combines symptoms of esophageal dysfunction with at least 15 eosinophils per high-power field after excluding alternative causes. Tezepelumab is a fully human monoclonal antibody that binds TSLP and prevents receptor signaling. AstraZeneca and Amgen share development costs and profits, with AstraZeneca leading development and Amgen leading manufacturing; the drug is already approved for severe asthma and chronic rhinosinusitis with nasal polyps in major markets.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Trial Design<\/td>\nRandomized, double-blind, placebo-controlled Phase III; 368 patients; two active doses<\/td>\n<\/tr>\n
Efficacy<\/td>\nBoth co-primary and all key secondary endpoints reportedly met (no numerical data)<\/td>\n<\/tr>\n
Durability<\/td>\nBenefits described as sustained through Week 52<\/td>\n<\/tr>\n
Safety<\/td>\nProfile described as consistent with approved indications (no numerical AE data)<\/td>\n<\/tr>\n
Strategic Reach<\/td>\nThird epithelial-driven inflammatory disease with positive Phase III evidence<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Upstream TSLP blockade provides clinically meaningful control of both inflammation and dysphagia across EoE patients, evidenced by dual-endpoint success at two doses and maintenance through Week 52.<\/p>\n

Bear case:<\/strong> The trial is statistically positive but differentiation may be limited once full data are compared with existing biologics and background care, given the absence of numerical data and a detailed safety table.<\/p>\n

InSilens Take<\/h4>\n

CROSSING achieved the clinically important combination of histologic and symptom success and extended TSLP validation into EoE. Direction remains provisional until full efficacy and safety data show whether the result is clinically large, broadly distributed and competitive rather than only statistically significant.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca and Amgen reported that the 368-patient Phase III CROSSING trial of tezepelumab in eosinophilic esophagitis met both co-primary endpoints at Week 24: histologic remission and improvement in dysphagia. Both tested doses also met…<\/p>\n","protected":false},"author":1,"featured_media":2731,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[180,16,441],"class_list":["post-2722","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-amgen","tag-astrazeneca","tag-eosinophilic-esophagitis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2722"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2722\/revisions"}],"predecessor-version":[{"id":2738,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2722\/revisions\/2738"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2731"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}